A Clinical Study for Developing Artificial Intelligence(AI)-Based Clustering Model for Personalized Medicine in Acute Respiratory Failure

April 23, 2026 updated by: Ryoung-Eun Ko, Samsung Medical Center

A Clinical Study for Developing AI-based Clustering Model for Personalized Medicine in Acute Respiratory Failure: Single Center, Prospective Cohort Study

The investigators will prospectively collect clinical information to develop a clustering analysis model and confirm phenotype for patients with acute respiratory failure who admit to the intensive care unit and require oxygen supply beyond a high flow nasal cannula, and a control group without acute respiratory failure. and clinical characteristics and prognosis will be compared.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

250

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

  1. Patients with acute respiratory failure admitted to the internal medicine intensive care unit of Samsung Seoul Hospital 1) Age 18 or older 2) Patients who require treatment with high flow nasal cannula (HFNC), non-invasive ventilation (NIV (BIPAP or CPAP)), or mechanical ventilation (MV) due to acute respiratory failure.
  2. The following patients (control group) admitted to the internal medicine intensive care unit of Samsung Seoul Hospital 1) Age 18 or older 2) Patients who do not require high flow nasal cannula (HFNC), non-invasive ventilation (NIV (BIPAP or CPAP)), or mechanical ventilation (MV) treatment

Description

# Inclusion Criteria:

- Acute Respiratory Failure group

Among patients admitted to the internal medicine intensive care unit at Samsung Seoul Hospital, if all of the following conditions are met:

1) Age 18 or older 2) Patients who require treatment with high flow nasal cannula (HFNC), non-invasive ventilation (NIV (BIPAP or CPAP)), or mechanical ventilation (MV) due to acute respiratory failure.

- control group For comparative analysis, among patients admitted to the internal medicine intensive care unit at Samsung Seoul Hospital who meet all of the following conditions, they are registered as a control group with the consent of the subjects and undergo the same research procedure.

  1. Age 18 or older

  2. Patients who do not require high flow nasal cannula (HFNC), non-invasive ventilation (NIV (BIPAP or CPAP)), or mechanical ventilation (MV) treatment

    • Exclusion Criteria:

If any of the following criteria applies, participants will not be permitted to participate in this clinical trial.

  1. Patients 48 hours after oxygen treatment (HFNC, NIV (BIPAP or CPAP), MV)
  2. Patients transferred from another hospital
  3. Patients with limitations in treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Acute Respiratory Failure group

Among patients admitted to the internal medicine intensive care unit at Samsung Seoul Hospital, if all of the following conditions are met:

  1. Age 18 or older
  2. Patients who require treatment with high flow nasal cannula (HFNC), non-invasive ventilation (NIV (BIPAP or CPAP)), or mechanical ventilation (MV) due to acute respiratory failure.
Control group

For comparative analysis, among patients admitted to the internal medicine intensive care unit at Samsung Seoul Hospital who meet all of the following conditions, they are registered as a control group with the consent of the subjects and undergo the same research procedure.

  1. Age 18 or older
  2. Patients who do not require high flow nasal cannula (HFNC), non-invasive ventilation (NIV (BIPAP or CPAP)), or mechanical ventilation (MV) treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hospital Mortality
Time Frame: From date of admission until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to 1 year
clinical outcomes - Hospital Mortality
From date of admission until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to 1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ICU Mortality
Time Frame: From date of ICU admission until the date of ICU discharge or date of death from any cause, whichever came first, assessed up to 6 months
clinical outcomes - ICU Mortality
From date of ICU admission until the date of ICU discharge or date of death from any cause, whichever came first, assessed up to 6 months
Hospital length of stay
Time Frame: From date of hospital admission until the date of hospital discharge, assessed up to 1 years
clinical outcomes - Hospital length of stay
From date of hospital admission until the date of hospital discharge, assessed up to 1 years
ICU length of stay
Time Frame: From date of ICU admission until the date of ICU discharge, assessed up to 6 months
clinical outcomes - ICU length of stay
From date of ICU admission until the date of ICU discharge, assessed up to 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Samsung Medical Center

Collaborators

Ministry of Science and ICT, Republic of Korea

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 14, 2023

Primary Completion (Estimated)

April 30, 2028

Study Completion (Estimated)

April 30, 2029

Study Registration Dates

First Submitted

June 24, 2024

First Submitted That Met QC Criteria

June 24, 2024

First Posted (Actual)

June 28, 2024

Study Record Updates

Last Update Posted (Actual)

April 28, 2026

Last Update Submitted That Met QC Criteria

April 23, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2023-08-003

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Respiratory Failure

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe